Source: Value in Health Regional Issues. Unidade: FCF
Subjects: MIELOMA MÚLTIPLO, REVISÃO SISTEMÁTICA
ABNT
VISACRI, Marilia Berlofa et al. Lenalidomide or thalidomide for transplant-ineligible patients with newly diagnosed multiple myeloma? an overview of systematic reviews. Value in Health Regional Issues, v. 43, p. 1-10 art. 100998, 2024Tradução . . Disponível em: https://dx.doi.org/10.1016/j.vhri.2024.100998. Acesso em: 25 ago. 2024.APA
Visacri, M. B., Ribeiro, M. C., Komoda, D. S., Duarte, B. K. L., Corrêa, C. R. S., Maia, F. de O. M., & Alves, D. F. dos S. (2024). Lenalidomide or thalidomide for transplant-ineligible patients with newly diagnosed multiple myeloma? an overview of systematic reviews. Value in Health Regional Issues, 43, 1-10 art. 100998. doi:10.1016/j.vhri.2024.100998NLM
Visacri MB, Ribeiro MC, Komoda DS, Duarte BKL, Corrêa CRS, Maia F de OM, Alves DF dos S. Lenalidomide or thalidomide for transplant-ineligible patients with newly diagnosed multiple myeloma? an overview of systematic reviews [Internet]. Value in Health Regional Issues. 2024 ; 43 1-10 art. 100998.[citado 2024 ago. 25 ] Available from: https://dx.doi.org/10.1016/j.vhri.2024.100998Vancouver
Visacri MB, Ribeiro MC, Komoda DS, Duarte BKL, Corrêa CRS, Maia F de OM, Alves DF dos S. Lenalidomide or thalidomide for transplant-ineligible patients with newly diagnosed multiple myeloma? an overview of systematic reviews [Internet]. Value in Health Regional Issues. 2024 ; 43 1-10 art. 100998.[citado 2024 ago. 25 ] Available from: https://dx.doi.org/10.1016/j.vhri.2024.100998